Lv1
80 积分 2024-11-05 加入
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
1个月前
已完结
Clinically relevant end points and new drug approvals for myeloma
1个月前
已完结
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
1个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
1个月前
已完结
Rounding rituximab dose to nearest vial size
2个月前
已完结
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
3个月前
已完结
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
3个月前
已完结
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study
3个月前
已完结
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
3个月前
已完结
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia
3个月前
已完结
皖公网安备34019202002308
